Nanotechnology has been proposed as a promising technique to enhance the efficacy of different drugs, including antiviral drugs. In the global fight against COVID-19, certain agents have already shown small progress, which could be enhanced by bringing together antiviral drugs and nanotechnology.
As the first step within this project, antiviral drugs currently used in clinical trials against COVID-19 such as Remdesivir, Favipiravir, Chloroquine, and Hydroxychloroquine are loaded on different nanoparticles, and their antiviral activity is tested. In the next step, different kinds of antiviral nanomaterials are prepared through 3D printing, followed by an assessment of their antiviral effect.
The project aims to develop low-cost and effective nanoparticles, which can be used in the treatment of viral diseases in general and COVID-19 in particular.
DATE and Venues of the project
Ain Shams University, Egypt
Egypt-Japan University of Science and Technology, Egypt
Institut Pasteur de Tunis, Tunisia
Charité Universitätsmedizin, Germany
Picture by Shutterstock/ Kateryna Kon